Rayldee Trial

There is nothing to start over with. Why would you continue to beat your head against a concrete wall? It’s like selling Rayaldee. The product is a sham, pricing is out of line, coverage is lacking and we have been told it is “business as usual”. More of the same, y’all.
True, however it’s about “ACCOUNTABILITY” held for all upper management calling the shots. After all they keep pointing the finger at us and terminating many.
 






True, however it’s about “ACCOUNTABILITY” held for all upper management calling the shots. After all they keep pointing the finger at us and terminating many.

Let’s look at the training and how we all have been instructed to promote this product. There is the problem and now that Ray is the acting NSM it is even more of a joke.
 






Population density and managed care have everything to do with it. Doesn’t hurt that AA is available will no notice to do in person programs.
Most populous states in US:
#1 California
#2 Texas
#3 Florida

open Medicaid in TX. Should be a home run
No local commercial or medicaid plan advantage in any region
Medicare is a moot point across all regions
 






Let’s look at the training and how we all have been instructed to promote this product. There is the problem and now that Ray is the acting NSM it is even more of a joke.
He wants the job but is not qualified. He will make our lives miserable just to prove he is worthy of the position. Everything has been tried before. It’s the price and coverage, end of story. Can’t do anything about that.
 


















He is more qualified than Queen Oreo Cookie. He will last as long as he can take the heat from Dr. Frostheimer in Miami. I give him six months.
Six months is about all of us have left in the Rayaldee ghetto. Just like Warsaw they have methodically reduced our numbers. Soon, the final solution will come.
 


















Looks like Patty has been on this post. Can’t even spell Rayaldee. Typical of her misspellings and oversights with each motivating email.
Yep. Patty mentioned culture on each of the monthly calls. What we all know is she created and left us a culture of mistrust, favoritism, paranoia and secrets. Oh, who can forget the unattainable IC plan, puppet RSMs, angry and demoralized sales reps? Good luck with trying to undo this culture that will permeate within Opko Renal for a very long time.
 






Oh, there is no “long time” for OPKO Renal. It’ll be out of business or be sold by mid-2022 if not sooner. It’s a big nothingburger. If it were a real burger Patty would’ve eaten it!
 






Oh, there is no “long time” for OPKO Renal. It’ll be out of business or be sold by mid-2022 if not sooner. It’s a big nothingburger. If it were a real burger Patty would’ve eaten it!
Agree……additionally it does not matter who leads the company’s sales force. They will be given 2 years and then be gone. It’s all about the price and coverage (lack there of). No secret. Fix that (and the can’t) and then maybe you have a chance. Board of directors need to be replaced.
 






Agree……additionally it does not matter who leads the company’s sales force. They will be given 2 years and then be gone. It’s all about the price and coverage (lack there of). No secret. Fix that (and the can’t) and then maybe you have a chance. Board of directors need to be replaced.
And the “covid” excuse is still being used. Shameful.
 




































Could not agree more, which mirrors the stock performance over the last few years. Despicable, downright pitiful.
Moving forward, the highest you will ever see the stock price is $5. I believe when Rayaldee was launched the stock price was around $10. It was downhill from there. What does that tell you? Pitiful is right.
 






    • OUCH!!!! More setbacks.

    • In 2014, Pfizer and OPKO Health Inc (NASDAQ: OPK) entered into a worldwide agreement to develop and commercial somatrogon for GHD.

  • Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.
  • The FDA has pushed back approval of Pfizer's once-weekly prospect.
  • Ascendis Pharma A/D (NASDAQ: ASND), after suffering its regulatory delay, won FDA approval for its once-weekly treatment for pediatric growth hormone deficiency (GHD) last month.